This trial is active, not recruiting.

Conditions critical limb ischemia, peripheral arterial disease, peripheral vascular disease
Treatments bone marrow concentration device, placebo procedure (sham)
Sponsor Zimmer Biomet
Start date June 2010
End date June 2016
Trial size 152 participants
Trial identifier NCT01049919, BB-IDE 13996, BBIO.CR.CT002


This trial will evaluate the safety and efficacy of concentrated bone marrow aspirate (cBMA) to prevent or delay major amputation and/or death in subjects with critical limb ischemia (CLI) due to severe peripheral arterial disease (PAD).

United States No locations recruiting
Other countries No locations recruiting

Study Design

Allocation randomized
Intervention model parallel assignment
Primary purpose treatment
Masking participant, outcomes assessor
Collection of autologous bone marrow aspirate and point-of-care concentration using the bone marrow concentration device, followed by intramuscular injection of concentrated bone marrow aspirate (cBMA) into the affected limb
bone marrow concentration device Bone marrow concentrate
Concentration of autologous bone marrow aspirate for intramuscular delivery to affected limb
(Sham Comparator)
Placebo procedure (sham) consists of simulated bone marrow aspiration followed by simulated intramuscular injections into the affected limb
placebo procedure (sham)
Sham bone marrow aspiration, sham delivery to affected limb

Primary Outcomes

Time to treatment failure
time frame: 52 weeks

Secondary Outcomes

Perfusion and quality of life measurements
time frame: Throughout 52 week follow-up

Eligibility Criteria

All participants at least 21 years old.

Inclusion Criteria: - Unilateral or bilateral lower extremity ischemia due to advanced peripheral arterial disease - Unsuitable for revascularization - Minor tissue loss (Rutherford Category 5) or ischemic rest pain (Rutherford Category 4) with ABI ≤ 0.6, or TBI ≤ 0.4, or TcPO2 ≤ 50 mm Hg - Competent to give consent - No current malignancy or history of previous malignancy within the last five years, with the exception of adequately treated non-melanoma skin cancer (evidence of standard preventative cancer screenings required) Exclusion Criteria: - Major tissue loss (Rutherford Category 6) - Diabetics on oral or insulin therapy with uncontrolled or untreated proliferative retinopathy (evidence of retinal exam required) - Poorly controlled diabetes mellitus with HbA1C > 10% (evidence of HbA1C test required) - Uncompensated congestive heart failure (New York Heart Association Class IV) and/or other conditions that preclude general anesthesia - Myocardial infarction or stroke within last 90 days - Elevated liver function tests (AST or ALT more than twice normal upper limit) - Renal disease (creatinine > 2.5 mg/dl) or chronic hemodialysis - White blood cell count < 3,000/µL or > 15,000/µL, platelet count < 100,000/µL, or hematocrit < 32% - Topical growth hormone therapy within last 90 days, or injected growth hormone therapy within last 180 days - Disease of central nervous system and/or other conditions that impair cognitive function - Two or more episodes of pulmonary embolus with a documented DVT in index leg or history of DVT in index leg without evidence of clot resolution - Current infection of index leg - Pregnant women (negative urine pregnancy test required) - Lower extremity venous disease with pitting edema in index leg - Recent history (in the 6 months prior to screening) of bone marrow disease or treatment with any medication or procedure which adversely affects the bone marrow and would prohibit transplantation - Current osteomyelitis in index leg - Existing HIV diagnosis - Organ transplant recipients - Known terminal disease process with life expectancy less than one year - Severe concomitant disease(s) or any additional condition(s) which the investigator feels constitute(s) criteria for exclusion of a particular subject - Major amputation required within 30 days - Inclusion in any other clinical study that may affect the outcome of this study - Uncorrected stenosis(es) of greater than 50% in the common and/or external iliac artery and/or common femoral artery of the index leg.

Additional Information

Official title MarrowStim PAD Kit for the Treatment of Critical Limb Ischemia (CLI) in Subjects With Severe Peripheral Arterial Disease (PAD)
Principal investigator Michael P. Murphy, MD
Description This is a prospective, randomized, double-blind, placebo controlled, multicenter trial intended for subjects with critical limb ischemia (CLI) that are unsuitable for revascularization. The investigational treatment utilizes autologous concentrated bone marrow aspirate (cBMA) at the point of care. The bone marrow aspirate is obtained from the subject's hip, concentrated with a bone marrow concentration device, and delivered intramuscularly to the affected limb. Subjects meeting the inclusion/exclusion criteria will be randomized to receive either the investigational treatment (cBMA) or a placebo control (sham treatment).
Trial information was received from ClinicalTrials.gov and was last updated in March 2017.
Information provided to ClinicalTrials.gov by Zimmer Biomet.